SNW.DE Живые сигналы | Максимизируйте прибыль с Getagraph.com

Live Chart Being Loaded With Signals

Commentary (30 апр. 2024 @ 18:35):

Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally...

Stats
Объем за сегодня	1 063.00
Средний объем	3 619.00
Рыночная капитализация	116.50B
EPS	€2.55 ( 2023-10-27 )
Last Dividend	€3.56 ( 2023-05-30 )
Next Dividend	€0 ( N/A )
P/E	25.79
ATR14	€0.111 (0.12%)

Sanofi SA Корреляция

10 Самые положительные корреляции

10 Самые отрицательные корреляции

Вы знали?

Корреляция - это статистический показатель, описывающий связь между двумя переменными. Он изменяется от -1 до 1, где -1 указывает на идеальную отрицательную корреляцию (при увеличении одной переменной другая уменьшается), 1 указывает на идеальную положительную корреляцию (при увеличении одной переменной другая увеличивается), а 0 указывает на отсутствие корреляции (между переменными нет связи).

Корреляцию можно использовать для анализа связи между любыми двумя переменными, не только акциями. Она широко используется в таких областях, как финансы, экономика, психология и т. д.

Sanofi SA Финансовые показатели

Annual	2023
Выручка:	€43.07B
Валовая прибыль:	€28.83B (66.95 %)
EPS:	€4.31

FY	2023
Выручка:	€43.07B
Валовая прибыль:	€28.83B (66.95 %)
EPS:	€4.31

FY	2022
Выручка:	€45.39B
Валовая прибыль:	€31.69B (69.83 %)
EPS:	€6.69

FY	2021
Выручка:	€39.18B
Валовая прибыль:	€26.92B (68.72 %)
EPS:	€4.96

Financial Reports:

No articles found.

Sanofi SA Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
€0 (N/A)	€0 (N/A)	€0 (N/A)	€3.56 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)

Sanofi SA Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 3.13 - low (4.25%) | Divividend Growth Potential Score: 5.64 - Stable (12.80%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	€2.07	2008-05-16
Last Dividend	€3.56	2023-05-30
Next Dividend	€0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	16	--
Total Paid Out	€45.47	--
Avg. Dividend % Per Year	0.00%	--
Score	1.98	--
Div. Sustainability Score	3.13
Div.Growth Potential Score	5.64
Div. Directional Score	4.38	--

Next Divdend (Est)
(2025-03-31)

€3.71 Estimate 3.11 %

Dividend Stability

0.25 Very Poor

Dividend Score

1.98

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for XETRA

Symbol	Title	Last dividend	Frequency	Yearly Dividend
VOS.DE	Ex Dividend Junior	2023-05-25	Sporadic	0.00%
EUZ.DE	Ex Dividend Knight	2023-06-08	Annually	0.00%
OEWA.DE	Ex Dividend Knight	2023-05-02	Annually	0.00%
ALD.DE	Ex Dividend Knight	2023-08-10	Quarterly	0.00%
HAG.DE	Ex Dividend Junior	2023-05-15	Annually	0.00%
RHK.DE	Ex Dividend Junior	2023-06-09	Sporadic	0.00%
BSL.DE	Ex Dividend Junior	2023-05-30	Annually	0.00%
IXX.DE	Ex Dividend Knight	2023-05-26	Annually	0.00%
SZG.DE	Ex Dividend Junior	2023-05-26	Annually	0.00%
DBK.DE	Ex Dividend Junior	2023-05-18	Sporadic	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.123	1.500	7.54	10.00	[0 - 0.5]
returnOnAssetsTTM	0	1.200	0	0	[0 - 0.3]
returnOnEquityTTM	0.0961	1.500	-0.0433	-0.0649	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	0	0.800	-5.00	-4.00	[1 - 3]
quickRatioTTM	0	0.800	-4.71	-3.76	[0.8 - 2.5]
cashRatioTTM	0	1.500	-1.111	-1.667	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	6.54	1.000	8.69	8.69	[3 - 30]
operatingCashFlowPerShareTTM	8.21	2.00	7.26	10.00	[0 - 30]
freeCashFlowPerShareTTM	5.61	2.00	7.20	10.00	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	0.673	1.000	2.11	2.11	[0.2 - 0.8]
operatingProfitMarginTTM	0.212	1.000	7.76	7.76	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0	0.800	-3.33	-2.67	[0.5 - 2]
Total Score				3.13

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	16.46	1.000	8.44	0	[1 - 100]
returnOnEquityTTM	0.0961	2.50	-0.0278	-0.0649	[0.1 - 1.5]
freeCashFlowPerShareTTM	5.61	2.00	8.13	10.00	[0 - 30]
dividendYielPercentageTTM	3.82	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	8.21	2.00	7.26	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0.752	1.500	8.32	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.179	1.000	8.03	0	[0.1 - 0.5]
Total Score				5.64

Sanofi SA

Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, liver care, physical and mental wellness, probiotics, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. Further, it has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration and license option agreement with Prellis Biologics, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.